Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-DOTA-30F11
- Development stage
- Preclinical
- Lead developer
- Fred Hutchinson Cancer Research Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-DOTA-30F11 is an experimental radiopharmaceutical designed for the treatment of hematologic malignancies, specifically acute myeloid leukemia (AML). It consists of the rat IgG2b monoclonal antibody 30F11, which targets the CD45 antigen (leukocyte common antigen) expressed on the surface of most hematopoietic cells and leukemic blasts. The antibody is conjugated to the beta-emitting radionuclide Lutetium-177 (177Lu) using the DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) chelator. While 177Lu offers favorable imaging properties due to its low-energy gamma emissions and a shorter path length compared to Yttrium-90, preclinical studies in murine models have shown that 177Lu-DOTA-30F11 may be less effective than its 90Y counterpart in treating disseminated leukemia, potentially due to differences in absorbed radiation doses and dose rates.
- Other names
- 177Lu-anti-CD45177Lu-DOTA-anti-CD45177Lu-labeled anti-CD45 antibody
02
Targets
PTPRC (Receptor-type tyrosine-protein phosphatase C)
Beyond the preview
Go deeper on 177Lu-DOTA-30F11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-DOTA-30F11.